Melanoma, version 4.2014
- PMID: 24812131
- DOI: 10.6004/jnccn.2014.0066
Melanoma, version 4.2014
Abstract
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.
Comment in
-
Sentinel lymph node biopsy for melanoma: a plea to let the data be heard.Ann Surg Oncol. 2014 Oct;21(11):3362-4. doi: 10.1245/s10434-014-3967-0. Epub 2014 Aug 8. Ann Surg Oncol. 2014. PMID: 25103536 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials